Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Teva Pharmaceuticals USA, Inc. et al v. Sandoz Inc. et al
Case Number:
1:09-cv-10112
Court:
Nature of Suit:
Judge:
Firms
Companies
- Momenta Pharmaceuticals Inc.
- Novartis AG
- Sandoz International GmbH
- Teva Pharmaceutical Industries Ltd.
Sectors & Industries:
-
July 16, 2013
Sandoz, Mylan Slip Teva Patent Suits Over MS Drug Research
Mylan Pharmaceuticals Inc. and Sandoz Inc. on Tuesday escaped almost identical infringement suits by Teva Pharmaceuticals Ltd. after they agreed to stop using its patented technology in seeking U.S. Food and Drug Administration approval for generic versions of Teva's multiple sclerosis drug Copaxone.
-
May 13, 2013
Teva Defends IP Suit Over Generic MS Drug Research
Teva Pharmaceuticals Ltd. on Monday defended its patent suit over rival Sandoz Inc.'s attempt to develop a generic version of its multiple sclerosis drug Copaxone, saying legal safe harbors that protect generic development do not apply in this case.
-
April 18, 2013
Generic MS Drug Development Was Protected, Sandoz Says
Sandoz Inc. asked a New York federal judge Wednesday to toss Teva Pharmaceuticals Industries Ltd.'s patent infringement suit, saying its use of a patented process as it developed a generic form of multiple sclerosis drug Copaxone was protected by the safe harbor exemption.